- Home
- CRDF vs DSGN Comparison
CRDF vs DSGN Comparison
Compare CRDF & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- DSGN
- Stock Information
- Founded
- CRDF 1999
- DSGN 2017
- Country
- CRDF United States
- DSGN United States
- Employees
- CRDF N/A
- DSGN N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- CRDF Health Care
- DSGN Health Care
- Exchange
- CRDF Nasdaq
- DSGN Nasdaq
- Market Cap
- CRDF 233.5M
- DSGN 208.9M
- IPO Year
- CRDF N/A
- DSGN 2021
- Fundamental
- Price
- CRDF $2.64
- DSGN $3.82
- Analyst Decision
- CRDF Strong Buy
- DSGN Hold
- Analyst Count
- CRDF 6
- DSGN 1
- Target Price
- CRDF $11.92
- DSGN $4.00
- AVG Volume (30 Days)
- CRDF 3.0M
- DSGN 95.8K
- Earning Date
- CRDF 07-29-2025
- DSGN 08-12-2025
- Dividend Yield
- CRDF N/A
- DSGN N/A
- EPS Growth
- CRDF N/A
- DSGN N/A
- EPS
- CRDF N/A
- DSGN N/A
- Revenue
- CRDF $545,000.00
- DSGN N/A
- Revenue This Year
- CRDF N/A
- DSGN N/A
- Revenue Next Year
- CRDF N/A
- DSGN N/A
- P/E Ratio
- CRDF N/A
- DSGN N/A
- Revenue Growth
- CRDF N/A
- DSGN N/A
- 52 Week Low
- CRDF $2.01
- DSGN $2.60
- 52 Week High
- CRDF $5.64
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- CRDF 34.68
- DSGN 45.61
- Support Level
- CRDF $2.31
- DSGN $3.76
- Resistance Level
- CRDF $4.52
- DSGN $4.19
- Average True Range (ATR)
- CRDF 0.37
- DSGN 0.22
- MACD
- CRDF -0.21
- DSGN -0.03
- Stochastic Oscillator
- CRDF 14.67
- DSGN 8.82
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.